1/69
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai |
|---|
No analytics yet
Send a link to your students to track their progress
Epinephrine improves bronchospasm primarily through stimulation of: A. a1 receptors B. B1 receptors C. B2 receptors D. Dopamine receptors
C. B2 receptors
Epinephrine supports blood pressure in shock through primarily: A. a1 vasoconstriction increasing SVR B. B2 vasodilation decreasing SVR C. Blocking calcium channels D. Increasing aldosterone production
A. a1 vasoconstriction increasing SVR
Which effect of epinephrine helps reduce airway swelling in anaphylaxis? A. B1 stimulation increases HR B. a1 vasoconstriction reduces capillary leak and edema C. B2 causes tachycardia D. Dopamine receptor stimulation increases renal blood flow
B. α1 vasoconstriction reduces capillary leak and edema
Which receptor profile best describes epinephrine? A. a1 only B. B1 only C. a1 + B1 + B2 D. Dopamine only
C. a1 + B1 + B2
Norepinephrine’s primary receptor target is: A. B2 B. a1 C. Dopamine receptors only D. Muscarinic receptors
B. a1
Dopamine is an adrenergic agonist that can stimulate: A. Only a1 B. Only B2 C. Dopamine receptors and adrenergic receptors depending on dose D. Only muscarinic receptors
C. Dopamine receptors and adrenergic receptors depending on dose
Dobutamine primarily stimulates: A. a1 B. B1 C. B2 only D. Muscarinic receptors
B. B1
A patient on dobutamine develops tachycardia. The nurse understands: A. This can occur due to B1 stimulation and may require dose adjustment B. This means the drug is ineffective C. This indicates hypokalemia only D. This is unrelated to dobutamine
A. This can occur due to β1 stimulation and may require dose adjustment
Which paired “best use” match is correct? A. Epinephrine = septic shock first-line pressor B. Norepinephrine = anaphylaxis first-line C. Dopamine = can support BP/CO but higher arrhythmia risk D. Dobutamine = primary drug for nasal congestion
C. Dopamine = can support BP/CO but higher arrhythmia risk